Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Qiagen N.V. (NY: QGEN )

45.00 -0.47 (-1.03%)
Streaming Delayed Price Updated: 12:24 PM EDT, May 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Qiagen N.V.

< Previous 1 2 3 Next >
QIAGEN and OncXerna Therapeutics Sign Licensing and Master Companion Diagnostic Agreements
From QIAGEN N.V.
Via Business Wire
QIAGEN receives U.S. FDA emergency use authorization for rapid portable test that can analyze over 30 samples per hour for SARS-CoV-2 antigen
From QIAGEN N.V.
Via Business Wire
QIAGEN Reports Full Results for Q2 and H1 2021
From QIAGEN N.V.
Via Business Wire
QIAGEN N.V. Conference Call on July 13 to Discuss Preliminary Q2 2021 Results
From QIAGEN N.V.
Via Business Wire
QIAGEN announces preliminary Q2 2021 results exceeding outlook, updates full-year 2021 outlook for declining COVID-19 test trends and plans new $100 million share repurchase program
From QIAGEN N.V.
Via Business Wire
QIAGEN’s NeuMoDx™ HAdV Quant Assay Secures CE-IVD Certification for Automated Testing to Detect Human Adenovirus Infections
From QIAGEN N.V.
Via Business Wire
QIAGEN launches the Workflow Configurator to help life science researchers simplify and optimize their laboratory experiments
From QIAGEN N.V.
Via Business Wire
QIAGEN Forms Strategic Alliance With Sysmex Corporation for Global Cancer Companion Diagnostics Development and Commercialization Using NGS and Plasma-Safe-SeqS Technology
From QIAGEN N.V.
Via Business Wire
Verogen Partners with QIAGEN to Deliver Innovative Solutions for Human Identification Laboratories
From Verogen
Via Business Wire
QIAGEN Partners with Verogen to Offer Broadest Portfolio for Human Identification, Including Next Generation Sequencing Solutions
From QIAGEN N.V.
Via Business Wire
QIAGEN Launches Dedicated CRISPR Products for Rapid and Simplified Analysis of Gene-Editing Experiments
From QIAGEN N.V.
Via Business Wire
QIAGEN Launches First FDA-approved Tissue Companion Diagnostic to Identify the KRAS G12C Mutation in NSCLC Tumours and Expand Precision Medicine Options in Lung Cancer
From QIAGEN N.V.
Via Business Wire
QIAGEN Partners With Mirati Therapeutics Inc. to Develop KRASG12C Companion Diagnostic for Non-Small Cell Lung Cancer (NSCLC)
From QIAGEN N.V.
Via Business Wire
QIAGEN Announces Creation of Scientific Advisory Board and Agenda for Annual General Meeting in June 2021
From QIAGEN N.V.
Via Business Wire
QIAGEN Receives U.S. FDA Emergency Use Authorization for Fast and Easy-to-Use Digital Test to Detect SARS-CoV-2 Coronavirus Antibodies
From QIAGEN N.V.
Via Business Wire
QIAGEN Exceeds Outlook in First Quarter 2021 Results, Reaffirms Sales Growth and Profitability Outlook for Full-Year 2021
From QIAGEN N.V.
Via Business Wire
QIAGEN Announces EZ2 Connect Instrument Line for Automated Sample Processing in Research, Forensics and Diagnostics
From QIAGEN N.V.
Via Business Wire
QIAGEN, in partnership with DiaSorin, announces the launch of the new LIAISON® LymeDetect® Assay based on QuantiFERON technology in countries accepting CE Mark for early diagnosis of Lyme Borreliosis
From QIAGEN N.V.
Via Business Wire
QIAGEN Launches artus Prep&Amp as CE-Marked SARS-CoV-2 Test Offering up to Threefold Increase in Daily Lab Testing Capacity
From QIAGEN N.V.
Via Business Wire
QIAGEN N.V. to Report First Quarter 2021 Results
From QIAGEN N.V.
Via Business Wire
QIAGEN Adds to COVID-19 Portfolio With New Ultra-Fast Sequencing Solution for High-Throughput Genomic Surveillance
From QIAGEN N.V.
Via Business Wire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.